Long Research

Dr. Micah Long hopes to improve the outcomes of organ transplant recipients by minimizing ischemia and reperfusion injury.  He is developing a scoring system to better evaluate PGD after lung transplant and trialing ascorbic acid to treat ischemia and reperfusion injury in organ transplant.

His interest in ascorbate and ischemia-reperfusion injury developed through his publication of the only time-matched, retrospective evaluation of ascorbic acid’s use in septic shock (Figure).  His work is the only study that showed an intense time-dependent impact of vitamin C therapy.  This realization led to his thesis that timely, resuscitative use of ascorbic acid may diminish ischemia-reperfusion injury in organ transplants.